PR Newswire All News ReleasesQwen · 实盘不做把握 9/10不做原因:无增量信息
北京时间·🕒 发布 15:19:00·⟳ 抓取 15:19:26 +26s·⚡ 决策 08-31 20:31:33 +5h12m·57.2 天前
律所发布ARS Pharmaceuticals证券集体诉讼投资者征集广告，无新增事实
本条是Schall, Brown & Schwartz律所就同一证券集体诉讼发布的投资者征集广告，与72小时内已处理的同一诉讼征集（SBS自身07:20 UTC及DJS Law Group 07:13 UTC）为同一具体催化，无新增金额、法院裁定、监管进展或经营事实。核心CVS Caremark覆盖延期已于6月24日披露并完成市场重定价。
📄 原文PR Newswire All News Releases↗ 原文
SPRY Investors Have Opportunity to Lead ARS Pharmaceuticals, Inc. Securities Fraud Lawsuit with SBS Law LOS ANGELES, Au…
不做 ARS Pharmaceuticals（SPRY.US）
本条为律所常规征集广告，非新增利空事件；同一诉讼已在72小时内被处理两次（SBS自身及DJS Law Group），核心负面事实（neffy/CVS Caremark覆盖延期）已于6月24日披露并完成重定价，无新增法院裁定、监管动作或经营事实，不构成交易催化
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
结论摘要
本条为律所通过PR Newswire发布的证券集体诉讼首席原告征集广告，属于常规律师营销行为。诉讼指控的实质内容（neffy纳入CVS Caremark处方集时间线存在延迟）已于2026年6月24日由公司披露并被市场消化。72小时内同一诉讼已有至少两条相同性质的征集提醒被处理为'不做'。本条无任何新增事实，不构成交易催化。
🔎 新鲜度:最早出现 2026-08-31 · 扩散 high · price-in 风险 high ↗
先例如何影响了这次决策
对本次决策的影响:本条为无新增事实的重复征集广告，不进入交易研究，无需先例定价
工具执行结果 · 成功 1 · 降级 0 · 失败 0 · 取消 0
- search_processed_events 成功 stock_tools HTTP · 331 ms
{"result": "search_processed_events:agent query=`ars pharmaceuticals securities fraud lawsuit | schall brown schwartz ars lawsuit | spry neffy cvs caremark formulary class action`；结构化索引覆盖完整 72 小时；旧记录兼容扫描近 71.2/72 小时、1063 条本臂决策(完整)，返回 2 条候选。\n• 08-31 07:20 UTC(CST 15:20) [ticker] 不做 SPRY.US (news_cen
原文全文
展开原文 · 2,672 字
SPRY Investors Have Opportunity to Lead ARS Pharmaceuticals, Inc. Securities Fraud Lawsuit with SBS Law
LOS ANGELES, Aug. 31, 2026 /PRNewswire/ -- Schall, Brown & Schwartz LLP ("SBS"), a national shareholder rights litigation firm, reminds investors of a class action lawsuit against ARS Pharmaceuticals, Inc. ("ARS" or "the Company") (NASDAQ: SPRY) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
Shareholders who purchased shares of SPRY during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointments. Appointment as lead plaintiff is not required to partake in any recovery.
CLASS PERIOD: March 9, 2026 to June 24, 2026
DEADLINE: October 5, 2026
If you are a shareholder who suffered a loss, click here to participate.
CASE DETAILS: According to the Complaint, the Company made false and misleading statements to the market. ARS knew or recklessly disregarded the risk of timeline problems related to CVS Caremark's addition of neffy to its formulary. The Company's guidance on the timeline for insurance coverage for neffy may shift considerably, impacting its commercialization. Based on these facts, the Company's public statements were false and materially misleading throughout the class period. When the market learned the truth about ARS, investors suffered damages.
We also encourage you to contact Brian Schall or David Schwartz of Schall, Brown & Schwartz LLP, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm's website at www.schallfirm.com, or by email at [email protected].
The class, in this case, has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member.
Join the case to recover your losses
WHY SBS? Schall, Brown & Schwartz LLP represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation. Bringing together the extensive experience and diverse skillsets of founding partners Brian Schall, Andrew Brown, and David Schwartz, SBS is dedicated to aggressively advocating for every investor.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.
CONTACT:
Schall, Brown & Schwartz LLP
Brian Schall, Esq.,
Andrew Brown, Esq.,
David Schwartz, Esq.,
www.schallfirm.com
Office: 310-301-3335
[email protected]
SOURCE Schall, Brown & Schwartz LLP
LOS ANGELES, Aug. 31, 2026 /PRNewswire/ -- Schall, Brown & Schwartz LLP ("SBS"), a national shareholder rights litigation firm, reminds investors of a class action lawsuit against ARS Pharmaceuticals, Inc. ("ARS" or "the Company") (NASDAQ: SPRY) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
Shareholders who purchased shares of SPRY during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointments. Appointment as lead plaintiff is not required to partake in any recovery.
CLASS PERIOD: March 9, 2026 to June 24, 2026
DEADLINE: October 5, 2026
If you are a shareholder who suffered a loss, click here to participate.
CASE DETAILS: According to the Complaint, the Company made false and misleading statements to the market. ARS knew or recklessly disregarded the risk of timeline problems related to CVS Caremark's addition of neffy to its formulary. The Company's guidance on the timeline for insurance coverage for neffy may shift considerably, impacting its commercialization. Based on these facts, the Company's public statements were false and materially misleading throughout the class period. When the market learned the truth about ARS, investors suffered damages.
We also encourage you to contact Brian Schall or David Schwartz of Schall, Brown & Schwartz LLP, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm's website at www.schallfirm.com, or by email at [email protected].
The class, in this case, has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member.
Join the case to recover your losses
WHY SBS? Schall, Brown & Schwartz LLP represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation. Bringing together the extensive experience and diverse skillsets of founding partners Brian Schall, Andrew Brown, and David Schwartz, SBS is dedicated to aggressively advocating for every investor.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.
CONTACT:
Schall, Brown & Schwartz LLP
Brian Schall, Esq.,
Andrew Brown, Esq.,
David Schwartz, Esq.,
www.schallfirm.com
Office: 310-301-3335
[email protected]
SOURCE Schall, Brown & Schwartz LLP
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
这条决策早于决策账本(2026-10-08 起逐条追加),没有追加记录。